FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803444356> ?p ?o ?g. }

• W2803444356 endingPage "e0006530" @default.
• W2803444356 startingPage "e0006530" @default.
• W2803444356 abstract "Background Ebola virus (EBOV) caused more than 11,000 deaths during the 2013–2016 epidemic in West Africa without approved vaccines or immunotherapeutics. Despite its high lethality in some individuals, EBOV infection can produce little to no symptoms in others. A better understanding of the immune responses in individuals who experienced minimally symptomatic and asymptomatic infection could aid the development of more effective vaccines and antivirals against EBOV and related filoviruses. Methodology/Principle findings Between August and November 2017, blood samples were collected from 19 study participants in Lagos, Nigeria, including 3 Ebola virus disease (EVD) survivors, 10 individuals with documented close contact with symptomatic EVD patients, and 6 control healthcare workers for a cross-sectional serosurvey and T cell analysis. The Lagos samples, as well as archived serum collected from healthy individuals living in surrounding areas of the 1976 Democratic Republic of Congo (DRC) epidemic, were tested for EBOV IgG using commercial enzyme-linked immunosorbent assays (ELISAs) and Western blots. We detected antibodies in 3 out of 3 Lagos survivors and identified 2 seropositive individuals not known to have ever been infected. Of the DRC samples tested, we detected antibodies in 9 out of 71 (12.7%). To characterize the T cell responses in the Lagos samples, we developed an anthrax toxin-based enzyme-linked immunospot (ELISPOT) assay. The seropositive asymptomatic individuals had T cell responses against EBOV nucleoprotein, matrix protein, and glycoprotein 1 that were stronger in magnitude compared to the survivors. Conclusion/Significance Our data provide further evidence of EBOV exposure in individuals without EVD-like illness and, for the first time, demonstrate that these individuals have T cell responses that are stronger in magnitude compared to severe cases. These findings suggest that T cell immunity may protect against severe EVD, which has important implications for vaccine development." @default.
• W2803444356 created "2018-06-01" @default.
• W2803444356 creator A5002978479 @default.
• W2803444356 creator A5004635492 @default.
• W2803444356 creator A5021025618 @default.
• W2803444356 creator A5034557317 @default.
• W2803444356 creator A5037554772 @default.
• W2803444356 creator A5038517318 @default.
• W2803444356 creator A5040021477 @default.
• W2803444356 creator A5058080572 @default.
• W2803444356 creator A5060013215 @default.
• W2803444356 creator A5069847194 @default.
• W2803444356 creator A5071646394 @default.
• W2803444356 creator A5074376915 @default.
• W2803444356 creator A5078539061 @default.
• W2803444356 date "2018-05-24" @default.
• W2803444356 modified "2023-10-13" @default.
• W2803444356 title "A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals" @default.
• W2803444356 cites W1972606960 @default.
• W2803444356 cites W1975375203 @default.
• W2803444356 cites W1977020956 @default.
• W2803444356 cites W1988126326 @default.
• W2803444356 cites W1995168510 @default.
• W2803444356 cites W2002206719 @default.
• W2803444356 cites W2006147963 @default.
• W2803444356 cites W2014609823 @default.
• W2803444356 cites W2030010127 @default.
• W2803444356 cites W2049704759 @default.
• W2803444356 cites W2076340825 @default.
• W2803444356 cites W2077149270 @default.
• W2803444356 cites W2081524511 @default.
• W2803444356 cites W2087409021 @default.
• W2803444356 cites W2094993149 @default.
• W2803444356 cites W2115445342 @default.
• W2803444356 cites W2117415699 @default.
• W2803444356 cites W2134066463 @default.
• W2803444356 cites W2167726155 @default.
• W2803444356 cites W2345513470 @default.
• W2803444356 cites W2360986492 @default.
• W2803444356 cites W2408843177 @default.
• W2803444356 cites W2472289993 @default.
• W2803444356 cites W2517688266 @default.
• W2803444356 cites W2544612685 @default.
• W2803444356 cites W2555954968 @default.
• W2803444356 cites W2575052398 @default.
• W2803444356 doi "https://doi.org/10.1371/journal.pntd.0006530" @default.
• W2803444356 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5991402" @default.
• W2803444356 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29795572" @default.
• W2803444356 hasPublicationYear "2018" @default.
• W2803444356 type Work @default.
• W2803444356 sameAs 2803444356 @default.
• W2803444356 citedByCount "4" @default.
• W2803444356 countsByYear W28034443562019 @default.
• W2803444356 countsByYear W28034443562021 @default.
• W2803444356 countsByYear W28034443562023 @default.
• W2803444356 crossrefType "journal-article" @default.
• W2803444356 hasAuthorship W2803444356A5002978479 @default.
• W2803444356 hasAuthorship W2803444356A5004635492 @default.
• W2803444356 hasAuthorship W2803444356A5021025618 @default.
• W2803444356 hasAuthorship W2803444356A5034557317 @default.
• W2803444356 hasAuthorship W2803444356A5037554772 @default.
• W2803444356 hasAuthorship W2803444356A5038517318 @default.
• W2803444356 hasAuthorship W2803444356A5040021477 @default.
• W2803444356 hasAuthorship W2803444356A5058080572 @default.
• W2803444356 hasAuthorship W2803444356A5060013215 @default.
• W2803444356 hasAuthorship W2803444356A5069847194 @default.
• W2803444356 hasAuthorship W2803444356A5071646394 @default.
• W2803444356 hasAuthorship W2803444356A5074376915 @default.
• W2803444356 hasAuthorship W2803444356A5078539061 @default.
• W2803444356 hasBestOaLocation W28034443561 @default.
• W2803444356 hasConcept C126322002 @default.
• W2803444356 hasConcept C159047783 @default.
• W2803444356 hasConcept C159654299 @default.
• W2803444356 hasConcept C203014093 @default.
• W2803444356 hasConcept C2522874641 @default.
• W2803444356 hasConcept C2776090121 @default.
• W2803444356 hasConcept C2777469322 @default.
• W2803444356 hasConcept C2777910003 @default.
• W2803444356 hasConcept C2779053233 @default.
• W2803444356 hasConcept C2909623084 @default.
• W2803444356 hasConcept C45189115 @default.
• W2803444356 hasConcept C71924100 @default.
• W2803444356 hasConcept C86803240 @default.
• W2803444356 hasConcept C8891405 @default.
• W2803444356 hasConceptScore W2803444356C126322002 @default.
• W2803444356 hasConceptScore W2803444356C159047783 @default.
• W2803444356 hasConceptScore W2803444356C159654299 @default.
• W2803444356 hasConceptScore W2803444356C203014093 @default.
• W2803444356 hasConceptScore W2803444356C2522874641 @default.
• W2803444356 hasConceptScore W2803444356C2776090121 @default.
• W2803444356 hasConceptScore W2803444356C2777469322 @default.
• W2803444356 hasConceptScore W2803444356C2777910003 @default.
• W2803444356 hasConceptScore W2803444356C2779053233 @default.
• W2803444356 hasConceptScore W2803444356C2909623084 @default.
• W2803444356 hasConceptScore W2803444356C45189115 @default.
• W2803444356 hasConceptScore W2803444356C71924100 @default.
• W2803444356 hasConceptScore W2803444356C86803240 @default.
• W2803444356 hasConceptScore W2803444356C8891405 @default.

• next